Immunomodulatory Effects of SGLT2 Inhibitors and Metformin in Managing Rheumatic Diseases: A Narrative Review
Naveenkumar Nallathambi1, Rahul Bisaralli2, Mahabaleshwar Mamadapur1,2
1Institute of Internal Medicine, Madras Medical College, Chennai, Tamilnadu, India.
Mediterranean Journal of Rheumatology
|October 28, 2024
Summary
Metformin shows potential as an add-on therapy for autoimmune rheumatic diseases. However, more research is needed on the effects of SGLT2 inhibitors in managing these conditions.
Area of Science:
- Rheumatology
- Endocrinology
- Immunology
Background:
- Limited research exists on the immunomodulatory effects of SGLT2 inhibitors and Metformin in rheumatic diseases.
- Understanding these effects is crucial for optimizing treatment strategies.
Purpose of the Study:
- To summarize existing clinical evidence on the impact of SGLT2 inhibitors and Metformin in managing rheumatic diseases.
- To identify knowledge gaps regarding their immunomodulatory effects.
Main Methods:
- A narrative review was conducted in November 2023.
- Literature search performed across Medline/PubMed, Scopus, Web of Science, Google Scholar, PubMed Central, Cochrane Library, and ScienceDirect.
- Studies were screened for relevance and pertinent outcome data.
Main Results:
- Metformin demonstrates multifaceted potential as an adjunctive therapy in autoimmune rheumatologic conditions.
- Limited literature is available on the clinical effects of SGLT2 inhibitors in rheumatic diseases.
Conclusions:
- Metformin offers promising avenues for enhancing patient outcomes in autoimmune rheumatic diseases.
- Further investigation into SGLT2 inhibitors' role in rheumatology is warranted.
Keywords:
Type 2 diabetes mellitusimmunomodulatory effectmetforminrheumatic diseasesodium-glucose cotransporter-2 (SGLT2) inhibitorsMore Related Videos
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
176
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
176
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
143
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
143
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
161
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
161
01:23Dipeptidyl Peptidase 4 Inhibitors
173
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
173
01:17Oral Hypoglycemic Agents: Sulfonylureas
193
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
193
01:29Drugs for Treatment of Ulcerative Colitis in IBD
124
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
124